Daniel Heintel

Ottakring, Austria

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Enfortumab vedotin plus pembrolizumab in treatment-naïve metastatic urothelial carcinoma patients: An Austrian real-world analysis.

Enfortumab vedotin plus pembrolizumab in treatment-naïve metastatic urothelial carcinoma patients: An Austrian real-world analysis.

Journal: International journal of cancer

Published: May 05, 2025

Real-world Evidence for Enfortumab Vedotin in Patients with Metastatic Urothelial Cancer: An Austrian Multicentre Study.

Real-world Evidence for Enfortumab Vedotin in Patients with Metastatic Urothelial Cancer: An Austrian Multicentre Study.

Journal: Clinical genitourinary cancer

Published: October 08, 2024

First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial.

First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial.

Journal: The Lancet. Oncology

Published: January 10, 2024

Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders.

Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders.

Journal: Cancer discovery

Published: April 26, 2021

Rationale for the combination of venetoclax and ibrutinib in T-prolymphocytic leukemia.

Rationale for the combination of venetoclax and ibrutinib in T-prolymphocytic leukemia.

Journal: Haematologica

Published: September 08, 2020

Recommendations for ibrutinib treatment in patients with atrial fibrillation and/or elevated cardiovascular risk.

Recommendations for ibrutinib treatment in patients with atrial fibrillation and/or elevated cardiovascular risk.

Journal: Wiener klinische Wochenschrift

Published: December 21, 2018

IKAROS expression in distinct bone marrow cell populations as a candidate biomarker for outcome with lenalidomide-dexamethasone therapy in multiple myeloma.

IKAROS expression in distinct bone marrow cell populations as a candidate biomarker for outcome with lenalidomide-dexamethasone therapy in multiple myeloma.

Journal: American journal of hematology

Published: August 01, 2016

Lenalidomide and dexamethasone for acute light chain-induced renal failure: a phase II study.

Lenalidomide and dexamethasone for acute light chain-induced renal failure: a phase II study.

Journal: Haematologica

Published: November 16, 2014

Insulin like growth factor binding protein 7 (IGFBP7) expression is linked to poor prognosis but may protect from bone disease in multiple myeloma.

Insulin like growth factor binding protein 7 (IGFBP7) expression is linked to poor prognosis but may protect from bone disease in multiple myeloma.

Journal: Journal of hematology & oncology

Published: August 25, 2014

Cereblon expression in multiple myeloma: not ready for prime time - response to Lodé et al.

Cereblon expression in multiple myeloma: not ready for prime time - response to Lodé et al.

Journal: British journal of haematology

Published: July 23, 2013

High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone.

High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone.

Journal: British journal of haematology

Published: November 20, 2012

Lipoprotein lipase in chronic lymphocytic leukaemia - strong biomarker with lack of functional significance.

Lipoprotein lipase in chronic lymphocytic leukaemia - strong biomarker with lack of functional significance.

Journal: Leukemia research

Published: October 29, 2012

Showing 1-12 of 13

Last Updated: 09/26/2026